malvidin has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Mo, J; Ni, J; Su, H; Xie, J; Xie, L; Xu, Y | 1 |
| Gu, X; Li, X; Zhang, C; Zhu, H; Zou, W | 1 |
2 other study(ies) available for malvidin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Structure-based design of human pancreatic amylase inhibitors from the natural anthocyanin database for type 2 diabetes.
Topics: Acarbose; Amylases; Animals; Anthocyanins; Databases, Factual; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Functional Food; Humans; Male; Mice; Mice, Inbred ICR; Pancreas; Structure-Activity Relationship; User-Computer Interface | 2020 |
Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats.
Topics: Animals; Anthocyanins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Glucose; Hypoglycemic Agents; Inflammation; Insulin Resistance; Lipid Metabolism; Male; Metformin; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley | 2021 |